Arcagy/ Gineco Group

This phase 3 trial compares the immunotherapy drug dostarlimab with standard chemotherapy in 260 women with advanced or recurrent endometrial cancer that has a specific DNA repair defect (MMR deficient). The goal is to see if dostarlimab can better delay cancer progression and im…

This phase 2 study tests whether adding relatlimab to the standard immunotherapy nivolumab can shrink tumors in people with locally advanced cervical cancer. About 77 participants will receive either the drug combination or nivolumab alone for 6 weeks. The main goal is to see how…